Laurus Labs gets approval to manufacture and market 2DG

On June 28, pharma major Dr Reddy's announced the commercial launch of 2DG at a maximum retail price of Rs 990 per sachet.


Last Updated on July 4, 2021 by The Health Master

Drug firm Laurus Labs on Friday said it has received the licence from Defence Research and Development Organisation to manufacture and market C-19 treatment drug 2-Deoxy-D-Glucose (2DG).

2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on C-19 patients in the country, Laurus Labs said in a regulatory filing.

“Laurus Labs has already applied with the Central Drugs Standard Control Organisation (CDSCO) for emergency use authorization (EUA) for 2DG,” it added.

On June 28, pharma major Dr Reddy’s announced the commercial launch of 2DG at a maximum retail price of Rs 990 per sachet.

Shares of Laurus Labs were trading at Rs 674.20 per scrip on BSE, up 1.08 per cent from the previous close.

Alembic gets USFDA nod for Nitrofurantoin Capsules USP

Axio Biosolution gets USFDA nod for Patch for bleeding control

Glenmark gets USFDA nod for generic Lung cancer drug

USFDA okays Tocilizumab for treatment of Covid-19

Zydus Cadila gets tentative nod from USFDA for Pemetrexed for Injection

Cipla gets USFDA nod for Inhalation product

Busting Myths of Vaccination

172 Drug Inspectors appointed as Medical Device Officer

These 5 Pharma giants join hands to test oral C-19 drug

DCGI denied approval for final trial of Sputnik Light to Dr…

NPPA fixes retail prices of 3 formulations

DCGI allows Cipla to import Moderna vaccine in India


Enter your email address:

Delivered by FeedBurner